Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the bioequivalence of a potential generic 600 mg
oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg oxcarbazepine
tablet, Trileptal, following a single 600 mg dose administered under fasting conditions.